查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1696299

全球即時診斷市場 - 2025 至 2033 年

Global Point of Care Diagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球即時診斷市場規模達到 154.6 億美元，預計到 2033 年將達到 326.3 億美元，在 2025-2033 年預測期內的複合年成長率為 8.7%。

即時診斷是指在病患照護地點或附近而不是在集中實驗室或醫院環境中進行的醫療診斷測試過程。這些測試旨在提供快速可靠的結果，幫助醫療保健提供者就患者的診斷和治療做出快速、明智的決定。目標是實現立即決策，而無需患者等待結果或前往另一個地點進行檢測。

即時診斷是一個快速發展的領域，它使醫療保健專業人員和患者能夠在護理地點或附近進行診斷測試。隨著應用和創新的不斷增加，即時診斷正在透過使診斷更快、更方便、更有效率來改變醫療保健服務。

市場動態：

促進因素與約束因素

即時診斷技術不斷進步

即時診斷（POC）技術的不斷進步是全球 POC 診斷市場發展的主要驅動力。分子診斷、微流體和生物感測器等新技術提高了即時診斷設備的準確性和速度。這些進步使得測試能夠快速完成，通常只需 30 分鐘，而且成本較低。

例如，2024 年 1 月，3EO Health 利用 3TR 技術進行 COVID-19 測試獲得了 FDA 緊急使用授權 (EUA)。 3TR 技術無需樣品製備、昂貴的耗材和複雜的設備，創造了一種全新類型的「高效能」即時分子檢測。高效率的定義是低成本、易於使用的分子檢測，每次檢測費用低於 20 美元，且無需製備樣品。

人工智慧 (AI) 在解釋測試結果方面發揮越來越重要的作用，可以提供更快、更準確的決策。人工智慧的即時診斷可以分析診斷資料並幫助臨床醫生以低成本做出更快、更準確的診斷。例如，2025 年 2 月，Avitia 推出了一個由人工智慧驅動的快速和即時癌症檢測平台。借助 Avitia 的平台，實驗室和臨床醫生現在可以進行先進的分子檢測。這項技術將使醫療團隊能夠準確地獲得癌症見解並以更低的成本更快地開始治療患者。

此外，2024 年 5 月，MolBio 宣布正在研究血液學、癌症、抗菌素抗藥性 (AMR)、下一代定序 (NGS)、症候群檢測等領域的許多開創性的即時診斷技術。該公司正在開發支援人工智慧 (AI) 的即時診斷測試 TruSight，用於各種血液學應用，包括全血球計數 (CBC)。該平台最終還可用於巴氏抹片檢查、瘧原蟲、精子數、鐮狀細胞疾病、地中海貧血等。

連接和資料整合問題

廣泛採用即時診斷技術的主要障礙之一是設備、醫療 IT 系統和電子健康記錄之間缺乏互通性。在許多醫療保健環境中，診斷設備、電子健康系統和患者資料平台並未整合，因此難以即時整合和存取患者資料。

由於即時診斷設備經常傳輸敏感的健康資料，因此維護這些資訊的安全性和隱私至關重要。資料整合不佳可能會使患者資訊暴露於未經授權的訪問，使得醫療保健提供者難以確保遵守資料保護法規（例如美國的 HIPAA 或歐洲的 GDPR）。

例如，根據《HIPAA雜誌》報道，2023 年 8 月，共報告了 2,300 萬份醫療記錄被洩露。在過去的 12 個月中，平均每月有 9,989,003 份醫療記錄被洩露。截至 2024 年 8 月 31 日的一年中，已發生 491 起涉及 500 筆或更多記錄的資料外洩事件，已知外洩記錄至少有 58,668,002 則。與連接和資料整合相關的問題，例如互通性挑戰、資料安全問題、手動資料輸入和雲端儲存效率低下，都是阻礙市場成長的重大障礙。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 產品片段
  • 技術片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 即時診斷技術不斷進步
      • 人口老化和慢性疾病加劇
    • 限制
      • 連接和資料整合問題
      • 來自替代診斷技術的競爭
    • 機會
      • 擴大居家檢測範圍
      • 數位與行動健康融合的進步
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：即時診斷市場（依產品分類）

  • 傳染病檢測產品
  • 血糖產品
  • 血氣和電解質產品
  • 血液學檢測產品
  • 尿液分析產品
  • 妊娠和生育測試產品
  • 腫瘤/癌症分析產品
  • 濫用藥物產品
  • 其他

第 6 章：即時診斷市場（按技術分類）

  • 橫向流動偵測
  • 免疫測定
  • 分子診斷
  • 微流體
  • 其他

第 7 章：即時診斷市場（按應用）

  • 傳染病
  • 血液學
  • 心臟病學
  • 內分泌學
  • 腫瘤學
  • 藥物檢測
  • 神經病學
  • 其他

第 8 章：即時診斷市場（以最終用戶分類）

  • 醫院和診所
  • 診斷實驗室
  • 門診手術中心 (ASC)
  • 家庭護理設置

第 9 章：即時診斷市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 拉丁美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第 11 章：公司簡介

  • BD
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • QuidelOrtho Corporation
  • QIAGEN
  • Trinity Biotech plc.
  • BioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Danaher Corporation
  • SEKISUI MEDICAL CO., LTD.

第 12 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 13 章：附錄

簡介目錄
Product Code: MD1063

The global point of care diagnostics market reached US$ 15.46 billion in 2024 and is expected to reach US$ 32.63 billion by 2033, growing at a CAGR of 8.7 % during the forecast period of 2025-2033.

Point-of-care diagnostics refers to a medical diagnostic testing process that takes place at or near the site of patient care, rather than in a centralized laboratory or hospital setting. These tests are designed to deliver rapid and reliable results that help healthcare providers make quick, informed decisions regarding patient diagnosis and treatment. The goal is to enable immediate decision-making without the need for a patient to wait for results or travel to another location for testing.

Point-of-care diagnostics is a rapidly advancing field that enables healthcare professionals and patients to perform diagnostic tests at or near the site of care. With growing adoption and innovations, point-of-care diagnostics is transforming healthcare delivery by making diagnostics faster, more accessible and more efficient.

Market Dynamics: Drivers & Restraints

Rising Advancements in Point-of-Care Diagnostics

Rising advancements in point-of-care (POC) diagnostics are a key driver of the global POC diagnostics market. New technologies like molecular diagnostics, microfluidics and biosensors have improved the accuracy and speed of point-of-care diagnostic devices. These advancements allow tests to be performed rapidly, often in less than 30 minutes at a low cost.

For instance, in January 2024, 3EO Health received FDA Emergency Use Authorization (EUA) for its COVID-19 test utilizing 3TR technology. 3TR technology eliminates the need for sample preparation, expensive consumables and complex equipment, creating a new category of "high efficiency" point-of-care molecular testing. High efficiency is defined as low-cost, easy-to-use molecular testing under $20 per test with no sample preparation required.

Artificial Intelligence (AI) is playing an increasing role in the interpretation of test results, offering quicker and more accurate decision-making. AI-powered point-of-care diagnostics can analyze diagnostic data and help clinicians make faster, more accurate diagnoses at low costs. For instance, in February 2025, Avitia launched an AI-powered platform for rapid & point-of-care cancer testing. With Avitia's platform, laboratories and clinicians now have access to advanced molecular testing. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster all at reduced costs.

Also, in May 2024, MolBio announced that it is working on many pathbreaking point-of-care technologies in the areas of hematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), syndromic testing, etc. The company is developing artificial intelligence (AI)-enabled point-of-care test TruSight for various hematology applications, including complete blood count (CBC). This platform could also be eventually used for PAP smears, malaria parasites, sperm counting, sickle cell disease, thalassemia, etc.

Connectivity & Data Integration Issues

One of the primary barriers to the widespread adoption of point-of-care diagnostic technologies is the lack of interoperability between devices, healthcare IT systems and electronic health records. In many healthcare environments, diagnostic devices, electronic health systems and patient data platforms are not integrated, making it difficult to consolidate and access patient data in real-time.

As point-of-care diagnostic devices often transmit sensitive health data, maintaining the security and privacy of this information is critical. Poor data integration can expose patient information to unauthorized access, making it difficult for healthcare providers to ensure compliance with data protection regulations (such as HIPAA in the U.S. or GDPR in Europe).

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records were reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The issues related to connectivity and data integration, such as interoperability challenges, data security concerns, manual data entry and cloud storage inefficiencies are significant barriers to the growth of the market.

Segment Analysis

The global point of care diagnostics market is segmented based on product, technology, application, end-user, and region.

Product:

The infectious disease testing products segment in the product is expected to dominate the global point of care diagnostics market with the highest market share

Infectious disease test products are diagnostic tools used to detect pathogens like bacteria or viruses in the body. They are crucial in identifying and controlling the spread of infectious diseases. Manufacturers offer various types of products, each tailored to detect specific pathogens or markers associated with specific diseases. Rapid tests provide quick results, often within minutes, and are commonly used for point-of-care testing.

Moreover, diagnostic testing capabilities for infectious diseases like influenza, SARS-CoV-2, Clostridium difficile, HIV, Group A streptococcus, STIs, and Lyme disease have significantly improved over the past few years due to significant launches, product innovations, and other various factors. For instance, in February 2023, Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR products for infectious diseases like MTB MDR, MT B, HBV, HCV, HIV, and HLA B27 have received licensing rights from the Central Drugs Standard Control Organization (CDSCO). The products will be manufactured in India in association with Mylab Discove1Y Solutions.

Also, growth for rapid and accurate diagnostics of infectious diseases, driven by early detection, decentralized testing, and antimicrobial resistance, is expanding. Government initiatives to improve diagnostic capabilities, especially in low- and middle-income countries, further support market expansion. These factors have solidified the segment's position in the global point of care diagnostics market.

Geographical Analysis

North America is expected to hold a significant position in the global point of care diagnostics market with the highest market share

North America, particularly the United States and Canada, holds a dominant position in the global POC diagnostics market. This market includes a wide range of diagnostic products such as blood glucose monitors, cardiac markers, pregnancy tests, infectious disease testing, and cholesterol testing.

The North American market is well-established with a high demand for diagnostic testing across various healthcare settings, including hospitals, clinics, urgent care centers, and even homecare environments. The increasing incidence of chronic diseases such as diabetes, cardiovascular diseases, respiratory disorders, and cancer is one of the primary drivers of the POC diagnostics market in North America. These conditions require regular monitoring and testing, which is facilitated by POC devices.

Key players in the region are receiving regulatory approvals and launching their products in the region. For instance, in January 2025, Roche received FDA clearance with a CLIA waiver for its cobas Liat molecular tests designed to diagnose sexually transmitted infections (STIs) at the point of care. Roche's cobas Liat molecular tests have met the regulatory standards for safety and effectiveness in the U.S. market. This is a significant milestone, as it ensures that the tests can be used legally and widely in healthcare settings. Thus, the above factors are consolidating the region's position as a dominant force in the global point of care diagnostics market.

Competitive Landscape

The major global players in the point of care diagnostics market include BD, QuidelOrtho Corporation, QIAGEN, Trinity Biotech plc., BioMerieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott Laboratories, Danaher Corporation, and SEKISUI MEDICAL CO., LTD. among others.

Key Developments

  • In February 2025, Avitia launched an AI-powered platform for rapid & point-of-care cancer testing. With Avitia's platform, laboratories and clinicians now have access to advanced molecular testing. This technology will allow a healthcare team to accurately obtain cancer insights and begin treating patients faster all at reduced costs.
  • In January 2025, Roche announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels at the point of care. These panels, including tests for chlamydia and gonorrhea (CT/NG) and chlamydia, gonorrhea, and Mycoplasma genitalium (CT/NG/MG), enable clinicians to diagnose and differentiate between multiple STIs with a single sample.
  • In May 2024, MolBio announced that it is working on many pathbreaking point-of-care technologies in hematology, cancer, anti-microbial resistance (AMR), next-generation sequencing (NGS), syndromic testing, etc. The company is developing artificial intelligence (AI)-enabled point-of-care test TruSight for various hematology applications, including complete blood count (CBC). This platform could also be used for PAP smears, malaria parasites, sperm counting, sickle cell disease, thalassemia, etc.
  • In January 2024, 3EO Health received FDA Emergency Use Authorization (EUA) for its COVID-19 test utilizing 3TR technology. 3TR technology eliminates the need for sample preparation, expensive consumables and complex equipment, creating a new category of "high efficiency" point-of-care molecular testing. High efficiency is defined as low-cost, easy-to-use molecular testing under $20 per test with no sample preparation required.
  • In April 2024, Roche Diagnostics India announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionize patient care. The claim extension of the NT-proBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D).

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global point of care diagnostics market report delivers a detailed analysis with 70+ key tables, more than 70+ visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Point-of-Care Diagnostics
      • 3.1.1.2. Rising Aging Population and Chronic Diseases
    • 3.1.2. Restraints
      • 3.1.2.1. Connectivity & Data Integration Issues
      • 3.1.2.2. Competition from Alternative Diagnostic Technologies
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion of Home-Based Testing
      • 3.1.3.2. Advancements in Digital and Mobile Health Integration
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Point of Care Diagnostics Market, By Product

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index By Product
  • 5.2. Infectious Disease Testing Products*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Blood Glucose Products
  • 5.4. Blood Gas & Electrolyte Products
  • 5.5. Hematology Testing Products
  • 5.6. Urinalysis Products
  • 5.7. Pregnancy and Fertility Testing Products
  • 5.8. Tumor/Cancer Profiling Products
  • 5.9. Drug-of-Abuse Products
  • 5.10. Others

6. Point of Care Diagnostics Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index By Technology
  • 6.2. Lateral Flow Assays*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Immunoassays
  • 6.4. Molecular Diagnostics
  • 6.5. Microfluidics
  • 6.6. Others

7. Point of Care Diagnostics Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index By Application
  • 7.2. Infectious Diseases*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology
  • 7.4. Cardiology
  • 7.5. Endocrinology
  • 7.6. Oncology
  • 7.7. Drug Testing
  • 7.8. Neurology
  • 7.9. Others

8. Point of Care Diagnostics Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals & Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Laboratories
  • 8.4. Ambulatory Surgery Centers (ASCs)
  • 8.5. Home Care Settings

9. Point of Care Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. BD*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. QuidelOrtho Corporation
  • 11.3. QIAGEN
  • 11.4. Trinity Biotech plc.
  • 11.5. BioMerieux SA
  • 11.6. F. Hoffmann-La Roche Ltd
  • 11.7. Siemens Healthineers AG
  • 11.8. Abbott Laboratories
  • 11.9. Danaher Corporation
  • 11.10. SEKISUI MEDICAL CO., LTD.

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us